NHY

N-HYDROXYUREA

Created:2006-03-22
Last modified:  2020-06-05

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count9
Chiral Atom Count0
Bond Count8
Aromatic Bond Count0
2D diagram of NHY

WebGL does not seem to be available.

This can be caused by an outdated browser, graphics card driver issue, or bad weather. Sometimes, just restarting the browser helps. Also, make sure hardware acceleration is enabled in your browser.

For a list of supported browsers, refer to http://caniuse.com/#feat=webgl.

Toggle HydrogenToggle Labels

Chemical Component Summary

NameN-HYDROXYUREA
Synonyms1-HYDROXYUREA
Systematic Name (OpenEye OEToolkits)hydroxyurea
FormulaC H4 N2 O2
Molecular Weight76.055
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs10.04O=C(N)NO
SMILESCACTVS3.341NC(=O)NO
SMILESOpenEye OEToolkits1.5.0C(=O)(N)NO
Canonical SMILESCACTVS3.341 NC(=O)NO
Canonical SMILESOpenEye OEToolkits1.5.0 C(=O)(N)NO
InChIInChI1.03 InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
InChIKeyInChI1.03 VSNHCAURESNICA-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB01005 
NameHydroxyurea
Groups approved
DescriptionHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.[A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects.[A262606]
Synonyms
  • Hidroxicarbamida
  • Hydroxycarbamid
  • Oxyurea
  • Hydroxyharnstoff
  • Carbamoyl oxime
Brand Names
  • Mylan-hydroxyurea
  • Hydroxyurea
  • Siklos
  • Riva-hydroxyurea
  • Eugia-hydroxyurea
IndicationHydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.[L41150]
Categories
  • Amides
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Antisickling Agents
  • Cytochrome P-450 CYP2D6 Inhibitors
ATC-CodeL01XX05
CAS number127-07-1

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Ribonucleoside-diphosphate reductase large subunitMHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSG...unknowninhibitor
Ribonucleoside-diphosphate reductase subunit M2MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARR...unknownmodulator
Urease subunit alphaMKINRQQYAESYGPTVGDRVRLADTDLGEVEKDYYYLGDEVNFGGGKVLR...unknownsubstrate
AlbuminMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...unknownbinder
Solute carrier organic anion transporter family member 1A2MGETEKRIETHRIRCLSKLKMFLLAITCAFVSKTLSGSYMNSMLTQIERQ...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL467
PubChem 3657
ChEMBL CHEMBL467
ChEBI CHEBI:44423
CCDC/CSD UREAOH12, UREAOH04, UREAOH01, UREAOH03, UREAOH